Arvinas (ARVN) Stock Forecast & Price Target

$29.65

+0.13 (+0.44%)

(As of 07/26/2024 ET)

Arvinas - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 16 Analyst Ratings

Based on 16 Wall Street analysts who have issued ratings for Arvinas in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 2 have given a hold rating, and 14 have given a buy rating for ARVN.

Consensus Price Target

$61.13
106.18% Upside

High Forecast	$90.00
Average Forecast	$61.13
Low Forecast	$20.00

According to the 16 analysts' twelve-month price targets for Arvinas, the average price target is $61.13. The highest price target for ARVN is $90.00, while the lowest price target for ARVN is $20.00. The average price target represents a forecasted upside of 106.18% from the current price of $29.65.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	12 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$61.13	$61.13	$59.73	$69.14
Forecasted Upside	106.18% Upside	79.61% Upside	73.73% Upside	92.55% Upside

Get Arvinas Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

Ad Crypto Swap Profits

625,000% Gain

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

ARVN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Arvinas Stock vs. The Competition

Type	Arvinas	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	106.18% Upside	3,123.46% Upside	9.17% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/17/2024	HC Wainwright 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$87.00	+173.58%
5/9/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$63.00 ➝ $60.00	+83.43%
5/8/2024	Wedbush 3 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$57.00	+69.19%
5/8/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$72.00 ➝ $68.00	+101.06%
3/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$65.00	+57.73%
2/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$26.00 ➝ $60.00	+30.61%
Get the Latest News and Ratings for ARVN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.
2/28/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$89.00 ➝ $90.00	+87.46%
2/28/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$95.00 ➝ $80.00	+66.63%
2/22/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$36.00 ➝ $55.00	+15.14%
2/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$70.00	+68.67%
12/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$32.00 ➝ $40.00	+38.07%
11/20/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$40.00	+91.20%
11/13/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $20.00	+31.06%
10/23/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$70.00 ➝ $55.00	+278.01%
9/7/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$70.00	+165.25%
2/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$81.00 ➝ $61.00	+92.01%
11/22/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$89.00 ➝ $74.00	+71.77%
10/25/2022	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Z. Jallah Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:38 AM ET.

ARVN Forecast - Frequently Asked Questions

What is Arvinas' forecast for 2024?: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Arvinas is $61.13, with a high forecast of $90.00 and a low forecast of $20.00.
Should I buy or sell Arvinas stock right now?: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares.
Does Arvinas's stock price have much upside?: According to analysts, Arvinas's stock has a predicted upside of 79.61% based on their 12-month stock forecasts.
What analysts cover Arvinas?: Arvinas has been rated by research analysts at HC Wainwright, Stifel Nicolaus, Wedbush, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Arvinas more than its competitors?: Analysts like Arvinas more than other "medical" companies. The consensus rating score for Arvinas is 2.88 while the average consensus rating score for "medical" companies is 2.72. Learn more on how ARVN compares to other companies.